MallInckrodt Plc (MNK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 103

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
MallInckrodt Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
MallInckrodt Plc, Medical Devices Deals, 2011 to YTD 2017 11
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company for up to USD410 Million 15
Biovectra to Acquire Manufacturing Facility from Sepracor Canada 17
Questcor Pharma Acquires Rights To Synacthen And Synacthen Depot 18
Mallinckrodt Completes Acquisition Of Rights To Roxicodone From Xanodyne Pharma 20
Venture Financing 21
InfaCare Pharma Raises USD3.5 Million in Venture Financing 21
Infacare Pharma Raises USD5.5 Million in Venture Financing 22
Infacare Pharma Raises USD1.3 Million in Venture Financing 23
Infacare Pharma Raises US$3.6 Million In First Tranche Of Series C Financing 24
CNS Therapeutics Secures An Additional US$0.05 Million In Venture Financing 25
Partnerships 26
Questcor Pharma Enters Into Licensing Agreement With European Company To Develop Novel Melanocortin Peptides 26
Mesoblast Enters into Agreement with Mallinckrodt Pharma 27
Valeo Pharma Enters into Distribution Agreement with Questcor Pharma for Synacthen Depot 28
INO Therapeutics Enters into Agreement with Lee's Pharma for Inomax 29
Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 30
Fuji Pharma Enters into Distribution Agreement with Mallinckrodt 31
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 32
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 33
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 35
BioVectra Enters Into Co-Marketing Agreement With Quanta BioSciences 36
Hi-Tech Pharmacal Enters Into Co-Marketing Agreement With Mallinckrodt For TussiCaps 37
Licensing Agreements 38
West Pharma Enters into Licensing Agreement with Mallinckrodt 38
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 39
Equity Offering 40
Cadence Pharma Completes Underwritten Public Offering Of Common Stock For US$81.75 Million 40
Cadence Pharma to Raise USD75 Million in Public Offering of Shares 42
Debt Offering 43
Mallinckrodt to Raise USD750 Million in Private Placement of Notes Due 2023 43
Mallinckrodt to Raise up to USD1.2 Billion in Private Placement of Notes 44
Asset Transactions 45
Intas Pharma May Acquire Generic Drug Unit from Mallinckrodt for USD1.5 Billion 45
Piramal Enterprises Acquires Intrathecal Therapy Business from Mallinckrodt for 203 Million 46
Acquisition 47
Mallinckrodt Acquires Ocera Therapeutics for up to USD117 Million 47
Mallinckrodt Acquires InfaCare Pharma 49
Mallinckrodt Acquires Stratatech 50
Mallinckrodt Pharma Acquires Therakos from Gores Group 51
Mallinckrodt Acquires Ikaria for up to USD2.3 Billion 53
Mallinckrodt Acquires Questcor Pharma for USD5.6 Billion 55
Mallinckrodt Completes Acquisition Of Cadence Pharma For US$1.4 Billion In Tender Offer 57
Questcor Pharma Completes Acquisition Of BioVectra, Contract Manufacturing Company, For US$101 Million 59
Mallinckrodt Completes Acquisition Of CNS Therapeutics For US$100 Million 60
MallInckrodt Plc - Key Competitors 62
MallInckrodt Plc - Key Employees 63
MallInckrodt Plc - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Recent Developments 68
Strategy And Business Planning 68
Oct 16, 2017: Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students 68
May 15, 2017: Mallinckrodt Opens New Global Centre for Medical Device R&D 69
Aug 18, 2016: Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment 70
Financial Announcements 71
Nov 07, 2017: Mallinckrodt Reports Earnings Results for Third Quarter of Fiscal 2017 71
Aug 08, 2017: Mallinckrodt Reports Earnings Results for Second Quarter of Fiscal 2017 73
May 08, 2017: Mallinckrodt Reports Earnings Results for First Quarter of Fiscal 2017 75
Feb 07, 2017: Mallinckrodt Reports Transition Period Results and Announces 2017 Guidance 77
Nov 29, 2016: Mallinckrodt Reports Fiscal 2016 Fourth Quarter and Full-Year Results 79
May 03, 2016: Mallinckrodt Reports Fiscal 2016 Second Quarter Results 81
Feb 02, 2016: Mallinckrodt Reports Fiscal 2016 First Quarter Results 83
Corporate Communications 85
Sep 20, 2017: Mallinckrodt Announces Election Of David Norton To Its Board Of Directors 85
May 19, 2017: Mallinckrodt Donates £100,000 to Ashford and St. Peter's Hospitals NHS Foundation Trust to Support Neonatal Care 86
Jan 04, 2017: Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of Mallinckrodt 87
Jun 16, 2016: Mallinckrodt Donates One Million Drug Deactivation Pouches To Support U.S. Fight Against Prescription Drug Abuse 88
May 23, 2016: Mallinckrodt Donates 250,000 Drug Deactivation Systems to ACT Missouri to Support Fight Against Prescription Drug Abuse 89
Legal and Regulatory 90
Sep 22, 2017: Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United States 90
Aug 04, 2017: Mallinckrodt Statement On Lawsuit Filed By Multnomah County, Oregon, Related To Opioid Products 91
Aug 02, 2017: Mallinckrodt Statement on U.S. DOJ Subpoena Related to Opioid Products 92
Other Significant Developments 93
Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters 93
Aug 30, 2017: Mallinckrodt Statement on Missouri Attorney General Investigation 95
Jul 27, 2017: Mallinckrodt Will Respond to Sen. McCaskill's Request for Information on Opioid Anti-Diversion and Suspicious Order Monitoring Activities 96
Jun 21, 2017: Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within Hospitals 97
Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims 98
Apr 03, 2017: Mallinckrodt Statement on DEA and USAOs Agreement in Principle 100
Jan 18, 2017: Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC Investigation 101
May 18, 2016: Mallinckrodt to Change Fiscal Year 102
Appendix 103
Methodology 103
About GlobalData 103
Contact Us 103
Disclaimer 103

List of Tables
MallInckrodt Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
MallInckrodt Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
MallInckrodt Plc, Deals By Therapy Area, 2011 to YTD 2017 10
MallInckrodt Plc, Medical Devices Deals, 2011 to YTD 2017 11
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company for up to USD410 Million 15
Biovectra to Acquire Manufacturing Facility from Sepracor Canada 17
Questcor Pharma Acquires Rights To Synacthen And Synacthen Depot 18
Mallinckrodt Completes Acquisition Of Rights To Roxicodone From Xanodyne Pharma 20
InfaCare Pharma Raises USD3.5 Million in Venture Financing 21
Infacare Pharma Raises USD5.5 Million in Venture Financing 22
Infacare Pharma Raises USD1.3 Million in Venture Financing 23
Infacare Pharma Raises US$3.6 Million In First Tranche Of Series C Financing 24
CNS Therapeutics Secures An Additional US$0.05 Million In Venture Financing 25
Questcor Pharma Enters Into Licensing Agreement With European Company To Develop Novel Melanocortin Peptides 26
Mesoblast Enters into Agreement with Mallinckrodt Pharma 27
Valeo Pharma Enters into Distribution Agreement with Questcor Pharma for Synacthen Depot 28
INO Therapeutics Enters into Agreement with Lee's Pharma for Inomax 29
Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 30
Fuji Pharma Enters into Distribution Agreement with Mallinckrodt 31
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 32
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 33
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 35
BioVectra Enters Into Co-Marketing Agreement With Quanta BioSciences 36
Hi-Tech Pharmacal Enters Into Co-Marketing Agreement With Mallinckrodt For TussiCaps 37
West Pharma Enters into Licensing Agreement with Mallinckrodt 38
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 39
Cadence Pharma Completes Underwritten Public Offering Of Common Stock For US$81.75 Million 40
Cadence Pharma to Raise USD75 Million in Public Offering of Shares 42
Mallinckrodt to Raise USD750 Million in Private Placement of Notes Due 2023 43
Mallinckrodt to Raise up to USD1.2 Billion in Private Placement of Notes 44
Intas Pharma May Acquire Generic Drug Unit from Mallinckrodt for USD1.5 Billion 45
Piramal Enterprises Acquires Intrathecal Therapy Business from Mallinckrodt for 203 Million 46
Mallinckrodt Acquires Ocera Therapeutics for up to USD117 Million 47
Mallinckrodt Acquires InfaCare Pharma 49
Mallinckrodt Acquires Stratatech 50
Mallinckrodt Pharma Acquires Therakos from Gores Group 51
Mallinckrodt Acquires Ikaria for up to USD2.3 Billion 53
Mallinckrodt Acquires Questcor Pharma for USD5.6 Billion 55
Mallinckrodt Completes Acquisition Of Cadence Pharma For US$1.4 Billion In Tender Offer 57
Questcor Pharma Completes Acquisition Of BioVectra, Contract Manufacturing Company, For US$101 Million 59
Mallinckrodt Completes Acquisition Of CNS Therapeutics For US$100 Million 60
MallInckrodt Plc, Key Competitors 62
MallInckrodt Plc, Key Employees 63
MallInckrodt Plc, Other Locations 64
MallInckrodt Plc, Subsidiaries 64

List of Figures
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
MallInckrodt Plc, Medical Devices Deals, 2011 to YTD 2017 11

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

MallInckrodt Plc (MNK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027